Biocorp and RxPack have announced a new distribution agreement giving RxPack the exclusive rights to commercialize Biocorp's Inspair inhaler sensor in Eastern Europe, Southeast Asia, South America, and the Middle East. Lindal had obtained the rights to market Inspair in those territories in 2018, and RxPack is a joint venture of Lindal and Coster which was formed in … [Read more...] about RxPack to distribute Biocorp’s Inspair inhaler sensor in certain territories
News
Ethris raises $26.3 million for development of inhaled mRNA therapies
Ethris GmbH said that it has closed a $26.3 million Series B financing round led by Laureus Capital, with proceeds earmarked for continued development of the company's ETH47 and ETH42 inhaled mRNA based therapies, which are currently in preclinical development. The company also said that Laureus Capital founder and CEO Christian Wawrzinek will become Managing … [Read more...] about Ethris raises $26.3 million for development of inhaled mRNA therapies
Gates Foundation awards $1.9 million grant to Aridis for development of inhaled mAbs
Aridis Pharmaceuticals announced that it has received an award of $1.9 million from the Bill & Melinda Gates Foundation to fund preclinical development of inhaled monoclonal antibodies against influenza and SARS-CoV-2. Aridis is developing both dry powder and liquid inhalation formulations in collaboration with Lumen Bioscience, the University of Alabama at … [Read more...] about Gates Foundation awards $1.9 million grant to Aridis for development of inhaled mAbs
Leyden Labs raises $140 million for development of intranasal vaccines
Intranasal vaccine developer Leyden Laboratories has closed a $140M Series B financing led by Casdin Capital and GV, the company said. Proceeds will go toward development of the company's pipeline, which includes its PanFlu intranasal mAb vaccine against both influenza A and B. Leyden Labs previously announced a €40 million Series A financing in March 2021. In … [Read more...] about Leyden Labs raises $140 million for development of intranasal vaccines
Opiant gets additional $2.2 million in BARDA funding for development of OPNT003 intranasal nalmefene
According to Opiant Pharmaceuticals, the company's contract with the Biomedical Advanced Research and Development Authority (BARDA) has been amended to provide an additional $2.2 million to support activities related to a 505(b)(2) NDA submission for OPNT003 nalmefene nasal spray for the treatment of opioid overdose. In July 2021, Opiant announced positive results … [Read more...] about Opiant gets additional $2.2 million in BARDA funding for development of OPNT003 intranasal nalmefene
Aculys Pharma gets rights to Valtoco nasal spray in Japan, Australia, and other Asia-Pacific countries
Aculys Pharma has acquired development and commercialization rights to Neurelis's Valtoco diazepam nasal spray in Japan, Australia, and other Asia-Pacific countries, including New Zealand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, South Korea, Thailand and Vietnam. Aculys, which launched in 2021, describes itself as "a biopharmaceutical … [Read more...] about Aculys Pharma gets rights to Valtoco nasal spray in Japan, Australia, and other Asia-Pacific countries
Opiant initiates Phase 2 trial of OPNT002 naloxone nasal spray for the treatment of alcoholism
Opiant Pharmaceuticals said that it has initiated a Phase 2 trial of its OPNT002 intranasal naltrexone for the treatment of alcohol use disorder that is expected to enroll approximately 300 patients, with results expected in 2023. The study will evaluate the efficacy of OPNT002 by measuring improvement in WHO drinking risk level. OPNT002 is formulated with … [Read more...] about Opiant initiates Phase 2 trial of OPNT002 naloxone nasal spray for the treatment of alcoholism
Lotus gets rights to market Ryaltris nasal spray in Singapore, Hong Kong, and Vietnam
Glenmark Pharmaceuticals announced that Lotus International, a wholly owned subsidiary of Lotus Pharmaceutical, has acquired the rights to commercialize Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray in Singapore, Hong Kong and Vietnam. Lotus will make an upfront payment as well as future payments based on regulatory and sales milestones. Glenmark … [Read more...] about Lotus gets rights to market Ryaltris nasal spray in Singapore, Hong Kong, and Vietnam
Pneumagen raises £3.8 million for Phase 2 development and manufacturing of Neumifil antiviral nasal spray
According to Pneumagen, the company has closed a £3.8 million funding round led by Thairm Bio and Scottish Enterprise, with proceeds intended to fund GMP manufacturing and Phase 2 development of its Neumifil carbohydrate binding module (mCBM) nasal spray for the prevention of respiratory viruses. Pneumagen initiated a Phase 1 study of Neumifil in November 2021 and … [Read more...] about Pneumagen raises £3.8 million for Phase 2 development and manufacturing of Neumifil antiviral nasal spray
CFF awards grant to Feldan Therapeutics for development of pulmonary delivery technology for CF
The Cystic Fibrosis Foundation has awarded funding to Feldan Therapeutics for development of the company's Feldan Shuttle technology for pulmonary delivery of drugs to treat cystic fibrosis. Neither the company nor the CFF disclosed the amount of the award, which was made under the CFF's Path to a Cure initiative. Social media posts from the CFF said that the purpose … [Read more...] about CFF awards grant to Feldan Therapeutics for development of pulmonary delivery technology for CF